Curated News
By: NewsRamp Editorial Staff
May 15, 2025
Cybin Collaborates with Thermo Fisher for Clinical Supply of CYB003 Treatment
TLDR
- Cybin's partnership with Thermo Fisher for CYB003 production boosts its market position in MDD treatments.
- Thermo Fisher supports Cybin's Phase 3 clinical supply and potential commercial manufacturing of CYB003 for MDD.
- CYB003 aims to revolutionize mental healthcare by offering innovative treatment options for major depressive disorder.
- Cybin's CYB003 shows promising Phase 3 trial results with a 100% response rate and 71% remission in MDD patients.
Impact - Why it Matters
This news highlights the progress in developing innovative psychedelic-based therapeutics for mental health conditions, addressing the significant unmet need in the field. The partnership with Thermo Fisher enhances Cybin's manufacturing capabilities, potentially advancing the treatment for major depressive disorder and offering hope for patients struggling with the condition.
Summary
Cybin partners with Thermo Fisher Scientific for Phase 3 clinical supply of CYB003, a deuterated psilocin treatment for major depressive disorder. The agreement includes drug substance manufacturing in South Carolina and capsule production in Ohio. CYB003 received FDA Breakthrough Therapy Designation in March 2024 and has shown promising Phase 2 results.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Cybin Collaborates with Thermo Fisher for Clinical Supply of CYB003 Treatment
